Table 1
Study characteristics
| Variable | Category | N = 148 | % |
|---|---|---|---|
| Gender | Male | 77 | 52 |
| Female | 71 | 48 | |
| Age | <50 years | 101 | 68.2 |
| ≥50 years | 47 | 31.8 | |
| Smoking Status | Yes | 18 | 12.2 |
| No | 130 | 87.8 | |
| Diabetes Mellitus | Yes | 7 | 4.7 |
| No | 141 | 95.3 | |
| Dyslipidemia | Yes | 5 | 3.4 |
| No | 143 | 96.6 | |
| TKI Type | Imatinib | 74 | 50 |
| Nilotinib | 74 | 50 |
Figure 1.
Comparison of systolic blood pressure changes in patients treated with imatinib and nilotinib.
Figure 2.
Comparison of diastolic blood pressure changes in patients treated with imatinib and nilotinib.
Table 2.
Changes in blood pressure before and after TKI therapy
| TKI Type | BP Parameter | Baseline (median [range], mmHg) | 12 Months (median [range], mmHg) | 12-Month Adjusted Mean ± 95% CI (mmHg) | Patients ≥130/80 mmHg at 12 mo n (%)1 | p-value (adjusted)2 |
|---|---|---|---|---|---|---|
| Imatinib | SBP | 112 (90–131) | 125 (100–134) | 125 (123–127) | 28 (37.8%) | <0.001 |
| DBP | 72 (60–90) | 81 (70–97) | 81 (79–83) | 31 (41.9%) | <0.001 | |
| Nilotinib | SBP | 111 (100–126) | 130 (110–146) | 132 (130–134) | 41 (55.4%) | <0.001 |
| DBP | 70 (60–83) | 83 (70–100) | 85 (83–87) | 45 (60.8%) | 0.006 |
Table 3
Difference in blood pressure after 12 months of TKI therapy based on drug type
| Blood Pressure | Imatinib Adjusted Mean ± 95% CI | Nilotinib Adjusted Mean ± 95% CI | Between-Group Adjusted Difference ± 95% CI | p-value (adjusted) |
|---|---|---|---|---|
| SBP (mmHg) | 125 (123–127) | 132 (130–134) | 7 (4–10) | <0.001 |
| DBP (mmHg) | 81 (79–83) | 85 (83–87) | 4 (2–6) | 0.006 |
Figure 3.
Comparison of blood pressure after 12 months of TKI treatment.